Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41584-020-0474-5 http://scihub22266oqcxt.onion/10.1038/s41584-020-0474-5 32733003!7391481!32733003     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Nat+Rev+Rheumatol 2020 ; 16 (10): 581-589 Nephropedia Template TP {{tp|p=32733003|t=2020. Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications |pdf=|usr=}}{{32733003}} gab.com Text Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications JO: Nat Rev Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=32733003 #FOAvip Reports of widespread thromboses and disseminated intravascular coagulation (DIC) in patients with coronavirus disease 19 (COVID-19) have been rapidly increasing in number. Key features of this disorder include a lack of bleeding risk, only mildly low platelet counts, elevated plasma fibrinogen levels, and detection of both severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and complement components in regions of thrombotic microangiopathy (TMA). This disorder is not typical DIC. Rather, it might be more similar to complement-mediated TMA syndromes, which are well known to rheumatologists who care for patients with severe systemic lupus erythematosus or catastrophic antiphospholipid syndrome. This perspective has critical implications for treatment. Anticoagulation and antiviral agents are standard treatments for DIC but are gravely insufficient for any of the TMA disorders that involve disorders of complement. Mediators of TMA syndromes overlap with those released in cytokine storm, suggesting close connections between ineffective immune responses to SARS-CoV-2, severe pneumonia and life-threatening microangiopathy. Twit Text FOAVip Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications ????Nat Rev Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=32733003 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32733003 #FOAvip English Wikipedia <ref>{{Cite pmid|32733003}}</ref> Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications #MMPMID32733003 Merrill JT; Erkan D; Winakur J; James JA Nat Rev Rheumatol 2020[Oct]; 16 (10): 581-589 PMID32733003show ga Reports of widespread thromboses and disseminated intravascular coagulation (DIC) in patients with coronavirus disease 19 (COVID-19) have been rapidly increasing in number. Key features of this disorder include a lack of bleeding risk, only mildly low platelet counts, elevated plasma fibrinogen levels, and detection of both severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and complement components in regions of thrombotic microangiopathy (TMA). This disorder is not typical DIC. Rather, it might be more similar to complement-mediated TMA syndromes, which are well known to rheumatologists who care for patients with severe systemic lupus erythematosus or catastrophic antiphospholipid syndrome. This perspective has critical implications for treatment. Anticoagulation and antiviral agents are standard treatments for DIC but are gravely insufficient for any of the TMA disorders that involve disorders of complement. Mediators of TMA syndromes overlap with those released in cytokine storm, suggesting close connections between ineffective immune responses to SARS-CoV-2, severe pneumonia and life-threatening microangiopathy. |Anticoagulants/therapeutic use[MESH] |Antiviral Agents/therapeutic use[MESH] |Betacoronavirus/*immunology[MESH] |COVID-19[MESH] |Complement System Proteins/immunology[MESH] |Coronavirus Infections/*complications/epidemiology/immunology/virology[MESH] |Cytokines/immunology[MESH] |Disseminated Intravascular Coagulation/drug therapy/immunology/pathology/virology[MESH] |Fibrinogen/analysis[MESH] |Humans[MESH] |Immunoglobulins, Intravenous/therapeutic use[MESH] |Immunosuppressive Agents/therapeutic use[MESH] |Pandemics[MESH] |Plasma Exchange/methods[MESH] |Platelet Count/methods[MESH] |Pneumonia, Viral/*complications/epidemiology/immunology/virology[MESH] |Risk Factors[MESH] |SARS-CoV-2[MESH] |Thrombosis/drug therapy/*immunology/pathology/virology[MESH]Emerging evidence of a COVID-19 thrombotic syndrome has treatment impl(epmc).pdf DeepDyve Pubget Overpricing